Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis
This study has been completed.
Information provided by (Responsible Party):
Promius Pharma, LLC
First received: October 23, 2012
Last updated: June 5, 2013
Last verified: October 2012
The purpose of this study is to determine whether Cloderm Cream is effective for topical treatment of moderate psoriasis over 28 days.
Drug: Cloderm Cream
||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||An Open-Label, Multicenter Study of the Efficacy of Cloderm® Cream (Clocortolone Pivalate, 0.1%) in the Treatment of Moderate Plaque Psoriasis for 28 Days
Primary Outcome Measures:
| Study Start Date:
| Primary Completion Date:
||March 2013 (Final data collection date for primary outcome measure)
Experimental: Cloderm Cream
Cloderm (clocortolone pivalate) Cream 0.1%, twice daily for 28 days
Drug: Cloderm Cream
Other Name: Cloderm Cream
The objective of this study is to estimate the efficacy of Cloderm Cream for topical treatment of moderate plaque psoriasis over 28 days using current standards for evaluation.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Subject understands the study procedures and agrees to participate by giving written informed consent.
- Subjects must be at least 18 years of age.
- Subjects must present with a clinical diagnosis of stable (at least 3 months) plaque-type psoriasis.
- Subjects with psoriasis involving 2 to 20% BSA, not including the face, scalp and intertriginous areas.
- Subjects must have an IGA Grade of 3 at the Baseline Visit.
Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline (Visit 2) (test will have a sensitivity of at least 25mIU/ml for human chorionic gonadotropin) and practice a reliable method of contraception or remain sexually inactive throughout the study.
All women of childbearing potential must be willing to undergo a urine pregnancy test at Visit 2 (Day 0), at Visit 4 (Day 14), and at Visit 5 (Day 28).
- Subjects must be in good general health as determined by the investigator and supported by the medical history and normal or not clinically significant abnormal vital signs (blood pressure and pulse).
- Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative or pustular psoriasis.
- Other inflammatory skin disease that may confound the evaluation of the plaque psoriasis (e.g., atopic dermatitis, contact dermatitis, tinea corporis).
- Presence of pigmentation, extensive scarring, pigmented lesions or sunburn which could interfere with the rating of efficacy parameters.
- History of psoriasis unresponsive to topical treatments.
- History of organ transplant requiring immunosuppression, HIV, or other immunocompromised state.
- Use within 180 days prior to Baseline Visit of biologic treatment for psoriasis (e.g., infliximab, adalimumab, etanercept, ustekinumab, or alefacept).
- Have received treatment for any type of cancer within 5 years of the Baseline Visit except for non-melanoma skin cancer and cervical cancer (in situ) are allowed within 1 year of the Baseline Visit.
- Use within 60 days prior to the Baseline Visit of: 1) immunosuppressive drugs (e.g., tacrolimus, pimecrolimus), 2) systemic antipsoriatic treatment (e.g., methotrexate, cyclosporine, hydroxyurea) or 3) oral retinoids (e.g., acitretin, isotretinoin).
- Use within 30 days prior to the Baseline Visit of: 1) systemic steroids, 2) PUVA therapy, 3) systemic anti-inflammatory agents (e.g., mycophenolate mofetil, sulfasalazine, 6-thioguanine), or 4) UVB therapy. Note: Inhaled, intraocular and intranasal steroids are allowed.
- Use within 14 days prior to the Baseline Visit of: 1) topical antipsoriatic drugs (e.g., salicylic acid, anthralin, coal tar, calcipotriene), 2) topical retinoids (e.g., tazarotene, tretinoin) or 3) topical corticosteroids.
- Subjects with known hypersensitivity to clocortolone pivalate or any component of Cloderm Cream.
- Subjects who have participated in a study of an investigational drug 60 days prior to the Baseline Visit.
- Subjects unable to comply with study requirements.
- Female subjects who are pregnant (or planning to become pregnant) or breast-feeding.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01714544
|Radiant Research, Inc.
|Cincinnati, Ohio, United States, 45249 |
|Oregon Medical Research
|Portland, Oregon, United States, 97223 |
|Austin, Texas, United States, 78759 |
|Research Across America
|Dallas, Texas, United States, 75234 |
|Madison Skin and Research, Inc.
|Madison, Wisconsin, United States, 53719 |
Promius Pharma, LLC
||Joanne M Fraser, PhD
No publications provided
||Promius Pharma, LLC
History of Changes
|Other Study ID Numbers:
|Study First Received:
||October 23, 2012
||June 5, 2013
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 09, 2014
Skin Diseases, Papulosquamous
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs